Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,648 recruiting studies in this area right now.
By phase
- Not applicable9,813
- Phase 24,456
- Phase 12,744
- Phase 1/Phase 21,689
- Phase 31,402
- Phase 2/Phase 3281
- Phase 4263
Top conditions
- Breast Cancer1,229
- Cancer660
- Prostate Cancer656
- Colorectal Cancer493
- Lung Cancer426
- Ovarian Cancer341
- Multiple Myeloma330
- Gastric Cancer298
- Acute Myeloid Leukemia293
- Pancreatic Cancer292
- Hepatocellular Carcinoma284
- Solid Tumor258
- Advanced Solid Tumor257
- Cervical Cancer232
- Head and Neck Cancer227
- Endometrial Cancer206
- Advanced Solid Tumors195
- Esophageal Cancer191
Leading sponsors
- M.D. Anderson Cancer Center452
- Fudan University315
- Sun Yat-sen University291
- Memorial Sloan Kettering Cancer Center288
- National Cancer Institute (NCI)287
- Mayo Clinic240
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences151
- City of Hope Medical Center144
- AstraZeneca133
- University Health Network, Toronto125
Where studies are running
- California1,426
- Texas641
- Arizona510
- Florida450
- Alabama420
- New York410
- Massachusetts339
- Maryland330
- New Jersey269
- Pennsylvania240
Recruiting studies20,648 total
- NCT04300062Recruiting
Rebiopsy of lung cancer after treatment no longer works
This trial studies patients with lung cancer whose disease has continued to grow despite immunotherapy. It involves taking a new tissue sample (a rebiopsy) to help doctors understand what changed during treatment and guide next steps.
Boulogne-BillancourtAges 18 years+ - NCT04300998Recruiting
CAR-T therapy study for older adults
This study looks at how well CAR-T cell therapy works and how safely it can be given to older adults. It is for people whose cancer or related blood condition has come back or did not respond, and who are receiving a standard (commercial) CAR-T product.
New York, New YorkAges 60 years+ - NCT04302025RecruitingPhase 2
Testing targeted and immunotherapy before lung cancer surgery
This trial studies whether giving different cancer medicines before (and sometimes after) surgery improves outcomes for people with early-stage, operable lung cancer that has certain tumor markers. It may help by trying to shrink or control the cancer early and lower the chance it comes back.
Duarte, CaliforniaAges 18 years+ - NCT04303117RecruitingPhase 1/Phase 2
Test drug PDS01ADC alone and with immunotherapy for Kaposi sarcoma
This Phase 1/2 study tests PDS01ADC, a targeted cancer drug, for advanced Kaposi sarcoma (KS). It also studies how well the drug works when added to the immunotherapy M7824, especially if KS has not responded to prior treatments.
Bethesda, MarylandAges 18–99 - NCT04303988RecruitingPhase 2
Trial for brain metastases from triple-negative breast cancer
This Phase 2 study tests a treatment for people with triple-negative breast cancer that has spread to the brain. It’s designed for situations where the cancer can’t be safely cured with surgery or focused radiation.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT04305548RecruitingPhase 2
Trabectedin for advanced mesenchymal chondrosarcoma with a specific gene fusion
This trial tests trabectedin, a chemotherapy medicine, for people with advanced mesenchymal chondrosarcoma that carries a specific gene fusion (HEY1-NCOA2). It’s designed for cases that have worsened despite prior chemotherapy, aiming to shrink tumors or control disease.
Prato, FirenzeAges 16 years+ - NCT04305834RecruitingPhase 2
Abemaciclib plus hormone pills for metastatic breast cancer in older adults
This Phase 2 study tests whether abemaciclib combined with standard hormone (endocrine) therapy can better control metastatic breast cancer in people age 70 and older. It may help if your cancer has already grown despite prior hormone therapy and/or other cancer medicines.
Duarte, CaliforniaAges 70 years+ - NCT04307901Recruiting
Test a capsule that checks the colon when colonoscopy isn’t finished
This trial tests whether a swallowable camera capsule can safely check the colon and find possible tumor-related issues when a standard colonoscopy can’t be completed. It may help people who can’t or don’t want another colonoscopy right away.
SvendborgAges 18 years+ - NCT04306432Recruiting
Check how cognitive tests change after brain tumor radiation
This trial studies how radiation therapy affects thinking and memory in adults with certain brain tumors. It may help doctors understand which patients are more likely to have cognitive side effects and how to measure them over time.
Copenhagen, Capital RegionAges 18–100 - NCT04308330RecruitingPhase 1
Vorinostat plus chemotherapy for advanced tumors in brain
This Phase 1 trial studies how safe and tolerable vorinostat is when combined with chemotherapy for cancers that have come back or are hard to treat, including tumors in the brain or spinal cord. It may help doctors find a better way to treat advanced solid tumors and CNS (brain/spinal cord) cancers.
Valhalla, New YorkAges 1–30 - NCT04312633Recruiting
Testing a new throat biopsy mapping method for Barrett’s disease
This study follows people for 5 years to see how well a new biopsy-mapping test (WATS3D) works during routine upper endoscopy. It may help doctors find Barrett’s esophagus changes earlier and better guide follow-up after treatment.
Bethpage, New YorkAges 18 years+ - NCT04314219RecruitingPhase 3
Preventing GVHD after leukemia stem cell transplant
This Phase 3 study tests whether giving post-transplant cyclophosphamide can better prevent a dangerous immune complication called GVHD compared with the usual standard medicines. You may be eligible if you are in remission from acute leukemia and planning a fully matched related-donor stem cell transplant.
RiyadhAges 14–65 - NCT04314752Recruiting
Study on multiple myeloma disparities in California patients
This study builds research tools to better understand and address differences in multiple myeloma outcomes for different groups. You may be able to help if you were diagnosed recently and live in California.
Sacramento, CaliforniaAges 21 years+ - NCT04317534RecruitingPhase 2
Pembrolizumab after lung cancer surgery versus observation
This trial tests whether pembrolizumab (an immunotherapy drug) given after complete surgery can lower the chance that early-stage lung cancer comes back. You’ll be compared to standard follow-up without extra treatment to see if the drug helps more people stay cancer-free.
Tampa, FloridaAges 18 years+ - NCT04316364RecruitingPhase 3
New immunotherapy plus chemo for resectable lung cancer
This Phase 3 trial studies whether an immunotherapy drug (SHR-1316) added to standard chemotherapy helps people live longer or delay cancer returning after surgery. It focuses on people with resectable non-small cell lung cancer (NSCLC) that has not been treated before.
Beijing, Beijing MunicipalityAges 18–70 - NCT04318678RecruitingPhase 1
CD123 CAR T-cell therapy for relapsed leukemia and related cancers
This early-phase study tests a lab-made immune therapy (CD123 CAR T cells) for children and young adults up to age 21 whose cancer has come back or didn’t respond to treatment. The goal is to see if these CAR T cells can find and attack cancer cells that carry a marker called CD123.
Memphis, TennesseeAges Up to 21 years - NCT04318730RecruitingPhase 2
Study of immunotherapy plus targeted drug for adrenal cancer
This trial tests whether combining camrelizumab (an immune treatment) with apatinib (a targeted drug) can shrink recurrent or metastatic adrenal cancer after standard treatment didn’t work. It may help some people control tumor growth when other treatments have already been tried.
Chengdu, SichuanAges 18 years+ - NCT04322578RecruitingPhase 2
Crizotinib versus standard chemotherapy for MET exon 14 lung cancer
This study compares crizotinib to standard chemotherapy for people with advanced (spread) non-small cell lung cancer that has a specific change called MET exon 14 skipping. The goal is to see which treatment works better and how safely it controls the cancer.
Changsha, HunanAges 18 years+ - NCT04324125Recruiting
Chemo plus immune therapy for HER2-positive advanced lung cancer
This trial studies whether adding an immune medicine (an antibody that helps your immune system recognize cancer, such as PD-1) to chemotherapy helps people with advanced HER2-positive non-small cell lung cancer. It may be aimed at people who have never had cancer treatment before.
Changsha, HunanAges 18 years+ - NCT04324151Recruiting
Pembrolizumab plus chemotherapy for lung cancer that may be removed
This trial tests whether adding pembrolizumab (an immune therapy) to standard chemotherapy helps people with certain non-squamous lung cancers that doctors think might be surgically removed. You might be considered if your planned treatment involves a “double platinum” chemotherapy or crizotinib and your cancer is potentially resectable.
Changsha, HunanAges 18 years+ - NCT04322617RecruitingPhase 2/Phase 3
Anlotinib plus immunotherapy for lung cancer after first treatment
This trial studies an oral targeted medicine (anlotinib) combined with an immunotherapy (checkpoint inhibitor) for lung cancer that did not respond to first-line chemo-immunotherapy. It may help shrink tumors and improve disease control after standard treatment has failed.
Changsha, HunanAges 18 years+ - NCT04322734Recruiting
Blood tests study immune and metabolism markers in neurodevelopment
This study looks for biological “signals” in blood—related to the immune system and metabolism—to better understand conditions like autism and other brain or development-related disorders. It may help researchers find markers that could guide future diagnosis or treatment.
Phoenix, ArizonaAges Up to 18 years - NCT04322890RecruitingPhase 2
Study for advanced lung cancer with gene mutations
This Phase 2 trial studies treatment strategies for people with stage IV non-small cell lung cancer (NSCLC) who have certain cancer gene mutations (like EGFR, ALK, or ROS1). It aims to see how different treatments affect survival and tumor response.
Changsha, HunanAges 18 years+ - NCT04324164Recruiting
Testing outcomes with EGFR pills for uncommon lung cancer mutations
This study looks at how well an EGFR-targeted pill (called an EGFR-TKI) works for people with advanced lung cancer that has an uncommon EGFR mutation. It may help doctors understand which patients benefit most and improve survival outcomes.
Changsha, HunanAges 18 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,648 recruiting oncology studies from the U.S. registry right now, out of 31,565 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.